Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alexander Burnett

Concepts (195)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Laparoscopy
7
2024
172
2.010
Why?
Endometrial Neoplasms
8
2024
137
1.860
Why?
Uterine Cervical Neoplasms
12
2022
275
1.690
Why?
Lymph Node Excision
5
2024
131
1.500
Why?
Neoplasm Staging
8
2024
738
0.890
Why?
Obesity, Morbid
2
2023
78
0.880
Why?
Natural Orifice Endoscopic Surgery
1
2023
4
0.870
Why?
Whole-Body Irradiation
2
2014
131
0.840
Why?
Gynecologic Surgical Procedures
4
2009
29
0.840
Why?
Sentinel Lymph Node Biopsy
1
2024
118
0.830
Why?
Metformin
2
2020
67
0.620
Why?
Hypoglycemic Agents
2
2020
174
0.590
Why?
Interleukin-11
2
2013
5
0.510
Why?
Neoplasm Recurrence, Local
3
2016
622
0.470
Why?
2-Pyridinylmethylsulfinylbenzimidazoles
1
2014
19
0.450
Why?
Prescription Drugs
1
2014
37
0.440
Why?
Hysterectomy
4
2023
88
0.440
Why?
Uterine Neoplasms
7
2007
60
0.430
Why?
Proton Pump Inhibitors
1
2014
83
0.430
Why?
Radiation Tolerance
1
2014
84
0.430
Why?
Radiation-Protective Agents
1
2013
72
0.410
Why?
Obesity
2
2016
1123
0.410
Why?
Robotics
2
2010
41
0.400
Why?
Female
32
2024
27053
0.380
Why?
Organotechnetium Compounds
1
2011
7
0.360
Why?
Lymphedema
1
2011
46
0.350
Why?
Vulvar Neoplasms
1
2011
58
0.340
Why?
Lower Extremity
1
2011
92
0.340
Why?
Radiopharmaceuticals
1
2011
202
0.330
Why?
Carcinoma, Squamous Cell
2
2011
326
0.330
Why?
Cystadenocarcinoma, Papillary
5
2006
14
0.310
Why?
Humans
34
2024
50419
0.290
Why?
Adult
19
2024
13561
0.290
Why?
Fertility
2
2009
28
0.290
Why?
Retroperitoneal Space
2
2024
27
0.280
Why?
Aged
16
2024
9738
0.280
Why?
Retrospective Studies
5
2023
6274
0.280
Why?
Middle Aged
18
2024
12579
0.270
Why?
Vagina
2
2023
43
0.270
Why?
Cervix Uteri
1
2006
42
0.250
Why?
Adenocarcinoma
1
2009
396
0.240
Why?
Topotecan
1
2005
17
0.240
Why?
Polyethylene Glycols
1
2005
84
0.230
Why?
Genital Neoplasms, Female
1
2004
41
0.220
Why?
Postoperative Complications
1
2011
1030
0.220
Why?
Ovarian Neoplasms
4
2014
449
0.210
Why?
Feasibility Studies
2
2024
389
0.210
Why?
Doxorubicin
1
2005
235
0.210
Why?
Uterus
1
2023
84
0.210
Why?
Lymph Nodes
1
2004
256
0.200
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2007
997
0.200
Why?
Gene Expression Regulation, Neoplastic
6
2011
831
0.200
Why?
Aged, 80 and over
5
2016
3233
0.180
Why?
Prospective Studies
3
2024
2378
0.170
Why?
Intestines
2
2013
152
0.160
Why?
Carcinoma
2
2011
137
0.140
Why?
Cell Proliferation
2
2020
980
0.140
Why?
Antineoplastic Agents
2
2007
1165
0.140
Why?
Cancer Vaccines
3
2014
80
0.140
Why?
Dendritic Cells
3
2014
135
0.140
Why?
Kruppel-Like Transcription Factors
2
2020
34
0.130
Why?
Cystadenocarcinoma, Serous
3
2005
71
0.130
Why?
Enterotoxins
2
2007
12
0.130
Why?
Pregnancy
1
2023
2444
0.130
Why?
Aromatase Inhibitors
2
2007
17
0.130
Why?
Nitriles
2
2007
52
0.130
Why?
Mice
4
2014
5659
0.120
Why?
Kallikreins
2
2006
18
0.120
Why?
Triazoles
2
2007
113
0.120
Why?
Receptor, erbB-2
2
2005
73
0.120
Why?
Neoplasms
1
2005
1248
0.120
Why?
Medical Oncology
2
2006
97
0.110
Why?
Lethal Dose 50
1
2014
12
0.110
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
1
2014
16
0.110
Why?
Hematopoiesis
1
2014
72
0.110
Why?
Hydrogen-Ion Concentration
1
2014
167
0.110
Why?
Ascites
1
2014
28
0.110
Why?
Safety
1
2014
77
0.110
Why?
Survival Analysis
2
2013
658
0.110
Why?
Stomach
1
2014
81
0.110
Why?
Spectrometry, Fluorescence
1
2013
47
0.100
Why?
Carcinoma, Endometrioid
2
2010
38
0.100
Why?
CD4-Positive T-Lymphocytes
1
2014
158
0.100
Why?
Incidence
1
2016
1027
0.100
Why?
Administration, Oral
1
2013
438
0.100
Why?
Papillomaviridae
3
2013
101
0.100
Why?
Animals
5
2014
13063
0.100
Why?
Cytokines
1
2014
602
0.090
Why?
Arkansas
1
2016
1974
0.080
Why?
Treatment Outcome
3
2011
5265
0.080
Why?
Cerclage, Cervical
1
2009
8
0.080
Why?
Estrogens
1
2011
225
0.080
Why?
Gene Amplification
2
2005
56
0.080
Why?
Genes, erbB-2
2
2005
8
0.080
Why?
Male
4
2014
25866
0.070
Why?
Carcinoma, Papillary
2
2005
47
0.070
Why?
Membrane Proteins
2
2007
337
0.070
Why?
Melanoma
1
2011
278
0.070
Why?
Intestinal Diseases
1
2007
26
0.070
Why?
Leiomyosarcoma
1
2007
20
0.070
Why?
Clostridium perfringens
1
2007
6
0.070
Why?
Carcinosarcoma
1
2007
18
0.070
Why?
Radiation Injuries, Experimental
1
2007
80
0.070
Why?
Endometrium
2
2020
40
0.060
Why?
Infertility, Female
1
2006
18
0.060
Why?
Oncogene Proteins, Viral
1
2005
52
0.060
Why?
Fellowships and Scholarships
1
2006
120
0.060
Why?
Dysgerminoma
1
2004
3
0.060
Why?
Medroxyprogesterone Acetate
1
2004
6
0.060
Why?
Patient Selection
1
2006
257
0.060
Why?
Gynecology
1
2004
48
0.050
Why?
Interleukin-6
1
2005
261
0.050
Why?
Immunotherapy, Adoptive
1
2005
161
0.050
Why?
Lymphatic Metastasis
1
2004
221
0.050
Why?
Drug Therapy, Combination
1
2005
387
0.050
Why?
Antibodies, Monoclonal
1
2007
460
0.050
Why?
Adolescent
4
2013
6453
0.050
Why?
Immunohistochemistry
4
2007
955
0.050
Why?
DNA-Binding Proteins
1
2005
410
0.050
Why?
Immunotherapy
1
2005
234
0.050
Why?
Cells, Cultured
3
2014
1563
0.050
Why?
Education, Medical, Graduate
1
2004
214
0.050
Why?
Lung Neoplasms
1
2007
597
0.050
Why?
Gene Expression Profiling
1
2005
1020
0.040
Why?
Preoperative Period
1
2020
46
0.040
Why?
PTEN Phosphohydrolase
1
2020
53
0.040
Why?
Receptors, Progesterone
1
2020
64
0.040
Why?
Estrogen Receptor alpha
1
2020
90
0.040
Why?
Cell Line, Tumor
3
2007
1393
0.040
Why?
Pilot Projects
1
2020
694
0.030
Why?
Claudin-3
2
2007
5
0.030
Why?
Claudin-4
2
2007
7
0.030
Why?
Mice, SCID
2
2007
171
0.030
Why?
Lymphocyte Activation
2
2007
169
0.030
Why?
Enzyme-Linked Immunosorbent Assay
2
2006
227
0.030
Why?
In Situ Hybridization, Fluorescence
2
2005
231
0.030
Why?
Apoptosis
1
2020
1092
0.030
Why?
Coculture Techniques
1
2014
140
0.030
Why?
p38 Mitogen-Activated Protein Kinases
1
2014
90
0.030
Why?
Human Umbilical Vein Endothelial Cells
1
2014
90
0.030
Why?
Combined Modality Therapy
2
2007
640
0.030
Why?
Optics and Photonics
1
2013
10
0.030
Why?
Antigens, Neoplasm
1
2014
148
0.030
Why?
Drug Resistance, Neoplasm
2
2005
315
0.030
Why?
Spectrum Analysis
1
2013
70
0.030
Why?
Uterine Cervical Dysplasia
1
2013
48
0.030
Why?
RNA, Messenger
2
2005
1085
0.020
Why?
Early Detection of Cancer
1
2013
162
0.020
Why?
Papillomavirus Infections
1
2013
165
0.020
Why?
Gene Silencing
1
2011
114
0.020
Why?
Prognosis
2
2005
1974
0.020
Why?
Antibody-Dependent Cell Cytotoxicity
1
2007
13
0.020
Why?
Neoplasm Transplantation
1
2007
83
0.020
Why?
Mast Cells
1
2007
55
0.020
Why?
Antineoplastic Agents, Hormonal
1
2007
49
0.020
Why?
Remission Induction
1
2007
208
0.020
Why?
Transforming Growth Factor beta
1
2007
134
0.020
Why?
Lymphocytes
1
2007
153
0.020
Why?
Intestinal Mucosa
1
2007
214
0.020
Why?
Recombinant Proteins
1
2007
477
0.020
Why?
Hypersensitivity, Delayed
1
2005
18
0.020
Why?
Papillomavirus E7 Proteins
1
2005
31
0.020
Why?
Sampling Studies
1
2005
36
0.020
Why?
Antigens, Viral
1
2005
42
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
224
0.020
Why?
Probability
1
2005
163
0.020
Why?
Statistics, Nonparametric
1
2005
189
0.020
Why?
Injections, Intraperitoneal
1
2005
59
0.020
Why?
Paraffin Embedding
1
2005
51
0.020
Why?
Biopsy, Needle
1
2005
179
0.010
Why?
Carboplatin
1
2004
54
0.010
Why?
Etoposide
1
2004
77
0.010
Why?
Xenograft Model Antitumor Assays
1
2005
210
0.010
Why?
Flow Cytometry
1
2007
472
0.010
Why?
B-Lymphocytes
1
2005
171
0.010
Why?
Receptors, Cell Surface
1
2005
117
0.010
Why?
Chemotherapy, Adjuvant
1
2004
119
0.010
Why?
Tumor Cells, Cultured
1
2005
453
0.010
Why?
Polymerase Chain Reaction
1
2005
447
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
568
0.010
Why?
Rats, Sprague-Dawley
1
2007
1556
0.010
Why?
Proportional Hazards Models
1
2005
416
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2005
400
0.010
Why?
Young Adult
1
2013
4075
0.010
Why?
T-Lymphocytes
1
2005
325
0.010
Why?
Clinical Competence
1
2006
403
0.010
Why?
Sensitivity and Specificity
1
2005
855
0.010
Why?
Case-Control Studies
1
2006
1152
0.010
Why?
Survival Rate
1
2005
906
0.010
Why?
Regression Analysis
1
2003
376
0.010
Why?
Disease-Free Survival
1
2003
439
0.010
Why?
Age Factors
1
2005
1118
0.010
Why?
Rats
1
2007
3262
0.010
Why?
Risk Assessment
1
2005
1268
0.010
Why?
Child
1
2004
6931
0.010
Why?
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description